Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as F-18 DPA-714 (BAY85-8102)
F-18 DPA-714 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| F-18 DPA-714 (BAY85-8102) | DRUG | Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT |
Inclusion Criteria: * Able to give fully informed consent in writing * Males or females aged \>/= 50 years * No significant disease or drug use * Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging: * Patient and designee capable of givi...
F-18 DPA-714 is an investigational small molecule positron emission tomography (PET) imaging agent developed by Bayer AG. It is being studied as a diagnostic imaging tool, including evaluation of neuroinflammation patterns in patients with probable Alzheimer's disease compared with healthy volunteers.
F-18 DPA-714 is being developed for diagnostic imaging. Its only recorded clinical study evaluated neuroinflammation patterns in patients with probable Alzheimer's disease versus healthy volunteers, and also assessed radiation dosimetry of the agent in healthy volunteers.
F-18 DPA-714 is developed by Bayer AG, which trades over the counter in the United States under the ticker BAYRY. The compound is also referenced by Bayer's internal code BAY85-8102.
F-18 DPA-714 is in Phase 1 clinical development. It is an investigational imaging agent and has not been approved by the FDA. Its single recorded Phase 1 trial has been completed, and no trials are currently active.
F-18 DPA-714 has been studied in one completed Phase 1 trial, NCT01009359, titled Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers. It enrolled 22 participants in Finland and the Netherlands.
Yes. F-18 DPA-714 is also known as BAY85-8102, Bayer's internal designation for the same compound. Both names refer to the same fluorine-18 labeled PET imaging agent.